Abstracts surgical procedures among younger patients for the management of DD. METHODS: Using a nationwide commercial claims database, a retrospective cohort was identified who had undergone LC (n = 2095) or OC (n = 5971) between 4 th quarter, 2005 through 1 st quarter, 2009. 2000 U.S. Census data was used to calculate age-adjusted temporal trends in the overall surgical procedure and logistic regression was used to determine the time trends in each surgical procedure, adjusting for age, gender, and the type of benefit plan. RESULTS: A total of 8,066 surgical procedures were performed during the study period (mean age = 53 ± 11, 55.7% Male). Quarterly mean number of surgical procedures(LC+OC) performed was 576 (SD = 39) and the annual mean number of LC+OC from 2006 to 2008 was 2297 (SD = 107). Quarterly agestandardized surgical procedures(LC+OC) for DD declined by 9.26% for patients younger than 45, whereas overall surgical rate increased by 3.2% for older patients. The odds of having a LC over OC declined by 8% each consecutive quarter (95% CI 0.91, 0.93) while controlling for other covariates. CONCLUSIONS: Data suggest that there was a slight decline over time in surgical procedures for younger patients. The reasons for the decline in surgical procedures for younger patients may be due to recent studies suggesting that DD is not more aggressive in younger patients as initially reported, and that the conservative medical treatment may be more appropriate with this population. 1950-1955. Longitudinal data across five years demonstrated increasing diagnosis rates with additional years of observation, according to a log function. Modeled for 10 years of observation, total diagnosed prevalence was estimated at 0.29% (R2 = 0.99); peak prevalence was 1.35% for males and 0.64% for females for those born in the early 1950s. CONCLU-SIONS: In each year examined, the claims-based prevalence of an HCV diagnosis was about 10% of the NHANES estimated prevalence (0.12% vs. 1.3%). Although diagnosed HCV prevalence increased with years of observation, the 10-year modeled diagnosis prevalence was only 22% of NHANES estimated prevalence. Like in NHANES, peak prevalence of HCV in claims was observed in patients born in the 1950s. This suggests that many patients have long-standing HCV infection and are at possible risk of decompensation. Further research is warranted to examine whether HCV-related advanced liver disease is more commonly coded in claims data. 4 Covance Market Access Services Inc., Gaithersburg, MD, USA OBJECTIVES: Low persistency for oral 5-ASA drugs is associated with increased risk of relapse of ulcerative colitis(UC) and subsequent costs. We constructed a one-year budget impact model to compare annual all-cause direct incremental costs(IC) of treatment for the health plan(HP) per mild-to-moderate UC patient using oral 5-ASA drugs and associated persistency rates(PRs). METHODS: Assuming a budget holder's perspective for a one-year horizon, the model analyzed the impact of PR on total UC related all-cause direct IC. PRs for 5-ASA drugs(mesalamine CR[CRM] 250mg 7% & 500mg 10%, balsalazide disodium[BD] 10%, olsalazine[OLS] 10%, mesalamine DR[DRM] 9%, multi matrix system mesalamine[MMX] 20%) were derived from published literature. UC patients within the HP were distributed to drugs based on September 2009 market share data and classified as persistent if they refilled within a timeframe of up to twice the duration of their prescription. Annual UC-related pharmacy costs were calculated using net wholesale acquisition cost, and additional allcause direct ICs for patients with/without relapse were cited from published literature. Sensitivity analyses varying net drug costs and PRs were performed to determine impact on health care costs. RESULTS: Average annual all-cause UC costs per patient were: $13,135 CRM-250; $13,065 CRM-500; $12,914 BD; $12,804 OLS, $12,688 DRM; $12,255 MMX. Inpatient costs were lower for MMX($5,667) as compared to market leader(DRM;$6,216) and lowest priced drug alternative(OLS;$6,343). Sensitivity analyses indicated higher savings/patient for MMX than DRM($462 vs. $30, respectively). The primary driver for inpatient cost differences was the frequency of relapse reduced by persistency. A health plan with 1 million covered lives(2,300 UC patients) can save $401,000($0.03 per member/month) by switching 50% of UC patients to MMX. CONCLUSIONS: This analysis illustrates the impact of medication persistence on reduction of UC relapse and associated health care costs. Health plans may achieve savings by including drugs with high PRs in their formulary.
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Milliman Inc., New York, NY, USA, 2 Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA OBJECTIVES: The National Health and Nutrition Examination Survey (NHANES) estimates chronic HCV infection prevalence at 1.3% of the US population or ∼3 million individuals, with a peak HCV antibody prevalence of 4.3% for those born in the 1950s. From NHANES we can assume that 79.7% of HCV antibody positive patients will not clear the virus; therefore we expect to observe 3% chronic HCV infection in this peak population. METHODS: Patients diagnosed with HCV (ICD-9 codes 070. 41, 070.44, 070.51, 070.54, 070.70, 070.71, V02.61 ) between 2002 and 2006 were identified in MedStat commercial health insurance claims. We calculated age-sex prevalence of diagnosis by birth year. A log-regression model was constructed to examine the relationship between prevalence of HCV diagnosis and number of observation years. RESULTS: The prevalence of patients with a HCV diagnosis in 2006 was 0.12%. The prevalence of patients with HCV diagnosis was consistent in each year's claims, peaking in those born between 1950-1955. Longitudinal data across five years demonstrated increasing diagnosis rates with additional years of observation, according to a log function. Modeled for 10 years of observation, total diagnosed prevalence was estimated at 0.29% (R2 = 0.99); peak prevalence was 1.35% for males and 0.64% for females for those born in the early 1950s. CONCLU-SIONS: In each year examined, the claims-based prevalence of an HCV diagnosis was about 10% of the NHANES estimated prevalence (0.12% vs. 1.3%). Although diagnosed HCV prevalence increased with years of observation, the 10-year modeled diagnosis prevalence was only 22% of NHANES estimated prevalence. Like in NHANES, peak prevalence of HCV in claims was observed in patients born in the 1950s. This suggests that many patients have long-standing HCV infection and are at possible risk of decompensation. Further research is warranted to examine whether HCV-related advanced liver disease is more commonly coded in claims data. 4 Covance Market Access Services Inc., Gaithersburg, MD, USA OBJECTIVES: Low persistency for oral 5-ASA drugs is associated with increased risk of relapse of ulcerative colitis(UC) and subsequent costs. We constructed a one-year budget impact model to compare annual all-cause direct incremental costs(IC) of treatment for the health plan(HP) per mild-to-moderate UC patient using oral 5-ASA drugs and associated persistency rates(PRs). METHODS: Assuming a budget holder's perspective for a one-year horizon, the model analyzed the impact of PR on total UC related all-cause direct IC. PRs for 5-ASA drugs(mesalamine CR[CRM] 250mg 7% & 500mg 10%, balsalazide disodium[BD] 10%, olsalazine[OLS] 10%, mesalamine DR[DRM] 9%, multi matrix system mesalamine[MMX] 20%) were derived from published literature. UC patients within the HP were distributed to drugs based on September 2009 market share data and classified as persistent if they refilled within a timeframe of up to twice the duration of their prescription. Annual UC-related pharmacy costs were calculated using net wholesale acquisition cost, and additional allcause direct ICs for patients with/without relapse were cited from published literature. Sensitivity analyses varying net drug costs and PRs were performed to determine impact on health care costs. RESULTS: Average annual all-cause UC costs per patient were: $13,135 CRM-250; $13,065 CRM-500; $12,914 BD; $12,804 OLS, $12,688 DRM; $12,255 MMX. Inpatient costs were lower for MMX($5,667) as compared to market leader(DRM;$6,216) and lowest priced drug alternative(OLS;$6,343). Sensitivity analyses indicated higher savings/patient for MMX than DRM($462 vs. $30, respectively). The primary driver for inpatient cost differences was the frequency of relapse reduced by persistency. A health plan with 1 million covered lives(2,300 UC patients) can save $401,000($0.03 per member/month) by switching 50% of UC patients to MMX. CONCLUSIONS: This analysis illustrates the impact of medication persistence on reduction of UC relapse and associated health care costs. Health plans may achieve savings by including drugs with high PRs in their formulary.
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